Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 3:24 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2113–2136 of 2,516 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Sequence Clear all

Conditions: Dilated Cardiomyopathy (DCM)
Interventions: RP-A701 is a recombinant viral vector composed of an AAV serotype rh.74 (AAVrh.74) capsid encapsulating the transgene, BCL2-associated Athanogene 3 (BAG3); Genetic
Lead sponsor: Rocket Pharmaceuticals Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 3
States / cities: San Diego, California • Rochester, Minnesota • Charleston, South Carolina

Conditions: Healthy
Interventions: PF-06463922, rifampin; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Human Health, Flavonoids, Carbonyl Stress
Interventions: High-Flavonoid Diet, Low-Flavonoid Diet; Dietary Supplement
Lead sponsor: North Carolina Agriculture & Technical State University; Other
Eligibility: 25 Years to 70 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Kannapolis, North Carolina

Conditions: Alcohol Use Disorder
Interventions: Placebo, Lacosamide 100 mg, Lacosamide 200 mg; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 21 Years to 50 Years · Male only
Enrollment: 4 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Obstructive Sleep Apnea, Hypertension
Interventions: Lorundrostat, Placebo; Drug
Lead sponsor: Mineralys Therapeutics Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 27
States / cities: Tuscaloosa, Alabama • Chandler, Arizona • Little Rock, Arkansas + 24 more

Conditions: Painful Peripheral Neuropathy, Diabetic Peripheral Neuropathic Pain (DPN), Chemotherapy Induced Peripheral Neuropathy (CIPN), Idiopathic Peripheral Neuropathy
Interventions: Pregabalin, Duloxetine, Placebo; Drug · Other
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years to 80 Years
Enrollment: 190 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 7
States / cities: Boston, Massachusetts • New York, New York • Rochester, New York + 4 more

Conditions: Healthy Volunteers
Interventions: TI-Inhalation Powder A, TI-Inhalation Powder B; Drug
Lead sponsor: Mannkind Corporation; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Chula Vista, California

Conditions: Healthy
Interventions: PF-07081532, Cyclosporine, Itraconazole; Drug · Device
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Healthy Subjects
Interventions: A: pacritinib, B: Placebo, C: moxifloxacin; Drug · Other
Lead sponsor: CTI BioPharma; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Evansville, Indiana

Conditions: Schizophrenia, Cerebellar Function, Condition
Interventions: Transcranial Magnetic Stimulation; Device
Lead sponsor: Northwell Health; Other
Eligibility: 18 Years to 60 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Healthy Volunteers
Interventions: Vonoprazan, Midazolam; Drug
Lead sponsor: Phathom Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Austin, Texas

Conditions: HIV Infections
Interventions: CYP and transporter probe substrates, BMS-955176, BMS-955176 plus CYP and transporter probe substrates; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 59 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Healthy
Interventions: Lansoprazole, Neratinib; Drug
Lead sponsor: Puma Biotechnology, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Drug Interaction
Interventions: Loperamide / Red Grapefruit Juice, Loperamide/ White Grapefruit Juice, Loperamide / Pink Grapefruit Juice; Drug
Lead sponsor: Johnson & Johnson Consumer and Personal Products Worldwide; Industry
Eligibility: 18 Years to 59 Years
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: HIV, Cardiovascular Diseases, Inflammation
Interventions: Aspirin, Clopidogrel; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 21 Years to 80 Years
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 2
States / cities: New York, New York

Conditions: Alcohol-Related Disorders, Alcohol Dependence, Alcoholism, Healthy Volunteer
Interventions: NMR-spectroscopy, Oral acamprosate; Procedure · Drug
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: 21 Years to 65 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2010
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Type2diabetes
Interventions: high intensity body-weight circuit; Behavioral
Lead sponsor: Kennesaw State University; Other
Eligibility: 40 Years to 65 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Kennesaw, Georgia

Conditions: Healthy Volunteers
Interventions: Ritlecitinib, Tolbutamide; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Biopsy, Fine-Needle, Biopsy, Fine-Needle/Methods, Endosonography
Interventions: FNA with and without a stylet; Device
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 137 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Papillary Carcinoma of Thyroid Gland, Metastatic Medullary Thyroid Cancer, Follicular Thyroid Cancer Lymph Node Metastasis
Interventions: Ferumoxytol, Nanoparticle MRI; Drug · Device
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Adrenal Insufficiency
Interventions: RSI sedation with etomidate/succinylcholine, RSI sedation with fentanyl/midazolam/succinylcholine; Drug
Lead sponsor: University of Tennessee; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006
U.S. locations: 1
States / cities: Chattanooga, Tennessee

Conditions: Gastro-enteropancreatic Neuroendocrine Tumor, Secondary Malignant Neoplasm of Liver
Interventions: magnetic resonance imaging (MRI); Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2023
U.S. locations: 1
States / cities: New York, New York

Conditions: Obstructive Sleep Apnea (OSA)
Interventions: Gefapixant, Placebo; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 4
States / cities: Hallandale, Florida • Hollywood, Florida • Atlanta, Georgia + 1 more

Conditions: Autism Spectrum Disorder
Interventions: Anatomical MRI Scan; Diagnostic Test
Lead sponsor: San Diego State University; Other
Eligibility: 40 Years to 65 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2021
U.S. locations: 1
States / cities: San Diego, California

Search by objective public record fields.

A Phase 1 AAV Gene Therapy Trial Evaluating Safety and Preliminary Efficacy of RP-A701 in Subjects With BAG3 Dilated Cardiomyopathy

A Study To Evaluate The Effect Of Rifampin On Pharmacokinetics Of PF-06463922 In Healthy Volunteers

Effects of Flavonoid Foods on Carbonyl Stress

Pilot Human Lab Study of Lacosamide in Alcohol Use Disorder (AUD)

A Study to Assess the Efficacy and Safety of Lorundrostat in Participants With Obstructive Sleep Apnea and Hypertension

SPENDD: Quantitative Sensory Testing and Analgesic Response for Painful Peripheral Neuropathy.

Comparison of 30 Units of TI (Technosphere® Insulin) Prepared With Insulin From Two Different Suppliers

A Drug-Drug Interaction Study to Examine the Impact of Itraconazole and Cyclosporine on PF-07081532 Pharmacokinetics in Overweight or Obese Adults

To Evaluate the Cardiac Safety and PK Following a Single Oral Dose Administration of Pacritinib in Healthy Subjects

Impact of Cerebellar TMS on Brain and Cognitive Functions in Schizophrenia: a Pilot Study

Evaluation of Effect of Vonoprazan on Midazolam Pharmacokinetics in Healthy Participants

Study on Effects of BMS-955176 on the Pharmacokinetics of Probe Substrates

Open-label PK Study to Evaluate Lansoprazole and Neratinib in Healthy Subjects

Loperamide Grapefruit Juice Interaction PK Trial

Antiplatelet Therapy in HIV

Acamprosate to Reduce Symptoms of Alcohol Withdrawal

High Intensity Body-weight Circuit Training Feasibility and Efficacy for in Middle Aged Persons With Type 2 Diabetes

Study to Evaluate the Effect of Multiple-Dose Ritlecitinib on the Pharmacokinetics (PK) of Tolbutamide

EUS-guided Fine Needle Aspiration (FNA) With and Without the Use of a Stylet

Pre-Operative Nodal Staging of Thyroid Cancer Using USPIO MRI: Preliminary Study

Evaluation of Etomidate on Adrenal Function in Trauma Patients

The Reproducibility Of Diffusion Weighted Magnetic Resonance Imaging For Neuroendocrine Tumor Liver Metastases

Safety and Tolerability of Gefapixant (MK-7264) in Participants With Obstructive Sleep Apnea (MK-7264-039)

Age-related Changes in Myeloarchitectonics Across Adulthood in Autism Spectrum Disorder